Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 7:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 707 matching trials from the live ClinicalTrials.gov search.
Filters: "mild cognitive impairment" Condition: Alzheimer's Disease Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01

NCT06247345
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ADEL-Y01 - healty participants, Placebo - Healthy Participants, ADEL-Y01 - MCI/AD, Placebo - MCI/AD
Drug
Lead sponsor
Alzheimer's Disease Expert Lab (ADEL), Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
6
States / cities
Anaheim, California • Lady Lake, Florida • Maitland, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 13, 2026, 7:14 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Crownlands Observing Progression With Neurons Study

NCT07611396
View directory record Official record
Conditions
Alzheimer s Disease, Mild Cognitive Impairment (MCI)
Interventions
Not listed
Lead sponsor
Crownlands
Industry
Eligibility
55 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Germantown, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 13, 2026, 7:14 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)

NCT02614131
View directory record Official record
Conditions
Healthy, Alzheimer's Disease, Mild Cognitive Impairment
Interventions
LY2599666, Solanezumab, Placebo SC, Placebo IV
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
Glendale, California • Marlton, New Jersey • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Oct 13, 2026, 7:14 PM EDT
Active, not recruiting Not applicable Interventional

Daily Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease

NCT04055376
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Dementia
Interventions
GENUS device (Active Settings), GENUS device (Sham Settings)
Device
Lead sponsor
Massachusetts Institute of Technology
Other
Eligibility
50 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 13, 2026, 7:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of CT1812 Treatment on Brain Synaptic Density

NCT03493282
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Active Treatment- CT1812 100 mg, Active Treatment- CT1812 300 mg, Placebo
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
50 Years to 85 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 13, 2026, 7:14 PM EDT
Not listed Not applicable Interventional

The Use of Transcranial Focused Ultrasound for the Treatment of Neurodegenerative Dementias

NCT04250376
View directory record Official record
Conditions
Mild Cognitive Impairment, Mild Dementia, Parkinson Disease, Alzheimer Disease
Interventions
Focused Transcranial Ultrasound
Device
Lead sponsor
Neurological Associates of West Los Angeles
Other
Eligibility
45 Years to 93 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 13, 2026, 7:14 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

NCT05267535
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Piromelatine 20 mg, Placebo
Drug
Lead sponsor
Neurim Pharmaceuticals Ltd.
Industry
Eligibility
60 Years to 85 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
32
States / cities
Costa Mesa, California • Long Beach, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 13, 2026, 7:14 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

NCT01922258
View directory record Official record
Conditions
Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
Interventions
Brexpiprazole, OPC-34712
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 90 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
28
States / cities
Imperial, California • Lakewood, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 13, 2026, 7:14 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

NCT05310071
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Aducanumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
60 Years to 85 Years
Enrollment
1,027 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
130
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 13, 2026, 7:14 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

An Objective Assessment Tool for Evaluating Functioning in Older Adults

NCT06489847
View directory record Official record
Conditions
Alzheimer Disease
Interventions
SPPB++ Application
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 13, 2026, 7:14 PM EDT
Completed Not applicable Interventional Results available

Stimulating Neural Activity to Improve Blood Flow and Reduce Amyloid: Path to Clinical Trials

NCT03543878
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Flicker
Device
Lead sponsor
Emory University
Other
Eligibility
50 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 13, 2026, 7:14 PM EDT
Completed Not applicable Interventional Results available

D-CARE - The Dementia Care Study: A Pragmatic Clinical Trial of Health System-Based Versus Community-Based Dementia Care

NCT03786471
View directory record Official record
Conditions
Dementia
Interventions
Health System-based Dementia Care, Community-based Dementia Care, Usual Care
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
2,176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Winston-Salem, North Carolina • Wilkes-Barre, Pennsylvania • Galveston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 13, 2026, 7:14 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

NCT02769065
View directory record Official record
Conditions
Alzheimer Disease, Healthy Volunteers
Interventions
TAK-071, Donepezil, TAK-071 Placebo, Donepezil Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 90 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Oct 13, 2026, 7:14 PM EDT
Completed Phase 2 Interventional Results available

Resveratrol for Alzheimer's Disease

NCT01504854
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Resveratrol, Placebo
Drug
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
50 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
26
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2016 · Synced Oct 13, 2026, 7:14 PM EDT
Not listed Not applicable Interventional

An Innovative Supportive Care Model for Dementia and Traumatic Brain Injury

NCT04495686
View directory record Official record
Conditions
Dementia, Mixed, Dementia Mild, Dementia Moderate, Traumatic Brain Injury, Alzheimer Disease
Interventions
Telehealth-delivered Care Coordination Program
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
21 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 13, 2026, 7:14 PM EDT
Terminated Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).

NCT02670083
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Crenezumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
66
States / cities
Phoenix, Arizona • Encino, California • Long Beach, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Oct 13, 2026, 7:14 PM EDT
Recruiting Not applicable Interventional

Music for Pain and Dementia

NCT07602283
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Mild Cognitive Impairment, Peer-bonded Caregiver, Caregiver
Interventions
Drumming session, Music-listening session
Behavioral
Lead sponsor
Yale University
Other
Eligibility
50 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 13, 2026, 7:14 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Retinal Imaging in Neurodegenerative Disease

NCT03233646
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, Multiple Sclerosis, Huntington Disease, Lewy Body Dementia, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis (ALS), APOE-4 Positive, Traumatic Brain Injury, Concussion, Post-Traumatic Stress Disorder, Down Syndrome, Neuro-Degenerative Disease, Normal Cognition
Interventions
Retinal and Choroidal Imaging
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 13, 2026, 7:14 PM EDT
Completed Not applicable Interventional Results available

Mild Cognitive Impairment and Obstructive Sleep Apnea

NCT01482351
View directory record Official record
Conditions
Obstructive Sleep Apnea, Mild Cognitive Impairment
Interventions
CPAP adherence intervention, Attention control intervention
Behavioral
Lead sponsor
George Mason University
Other
Eligibility
55 Years to 89 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Abington, Pennsylvania • Philadelphia, Pennsylvania • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 13, 2026, 7:14 PM EDT
Terminated Not applicable Interventional Results available

Napping, Sleep, Cognitive Decline and Risk of Alzheimer's Disease

NCT03256539
View directory record Official record
Conditions
Sleep, Alzheimer Disease, Cognitive Impairment, Aging, CBT
Interventions
Sleep intervention, Placebo intervention
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 13, 2026, 7:14 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia

NCT02783573
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Lanabecestat, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
55 Years to 85 Years
Enrollment
1,722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
90
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 13, 2026, 7:14 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Use of a Mobile Brain-Body Imaging Approach to Evaluate the Effects of Rhythmic Auditory Stimulation on Gait and Brain Function in Alzheimer's Disease

NCT07659964
View directory record Official record
Conditions
Alzheimer Disease (AD), Mild Cognitive Impairment (MCI)
Interventions
Metronome
Other
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
50 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 13, 2026, 7:14 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease

NCT05063539
View directory record Official record
Conditions
Alzheimer Disease
Interventions
LY3372689, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years to 85 Years
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
35
States / cities
Canoga Park, California • Fresno, California • Irvine, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 13, 2026, 7:14 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset

NCT01931566
View directory record Official record
Conditions
Mild Cognitive Impairment Due to Alzheimer's Disease
Interventions
Pioglitazone, Pioglitazone placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
65 Years to 83 Years
Enrollment
3,494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
34
States / cities
Phoenix, Arizona • Sun City, Arizona • Long Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 13, 2026, 7:14 PM EDT